SCHEDULE: Baillie Gifford Holds 7.5% Stake in Denali Therapeutics

Baillie Gifford & Co. has reported a beneficial ownership of 7.5% in Denali Therapeutics Inc. common stock as of June 30, 2026.

Summary

• Baillie Gifford & Co. has filed a Schedule 13G, indicating their beneficial ownership of Denali Therapeutics Inc. common stock.
• As of June 30, 2026, Baillie Gifford & Co. beneficially owns 11,960,230 shares, representing 7.5% of the class of securities.
• The filing specifies sole voting power for 11,915,890 shares and sole dispositive power for 11,960,230 shares.
• The securities are held by Baillie Gifford & Co. and/or its investment adviser subsidiaries on behalf of various institutional clients.
• Baillie Gifford & Co. certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but stable institutional holding without immediate indications of aggressive action or distress.

Positives

• Significant institutional ownership by Baillie Gifford & Co., indicating confidence in Denali Therapeutics.
• Baillie Gifford & Co. holds a substantial 7.5% stake, suggesting a long-term investment perspective.
• The filing confirms that shares are held in the ordinary course of business, not for hostile takeover or control purposes.

Negatives

• No specific negative financial or operational data is presented in this Schedule 13G filing.

Risks

• The filing does not explicitly detail risks; however, the concentration of ownership by a single entity could be a factor in future corporate actions or market liquidity.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance regarding Denali Therapeutics' future performance.

Management Comments

• "Securities reported on this Schedule 13G as being beneficially owned by Baillie Gifford & Co. are held by Baillie Gifford & Co. and/or one or more of its investment adviser subsidiaries... on behalf of investment advisory clients..."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities..."

Industry Context

StockSavvy.ai notes that significant institutional holdings, like this one by Baillie Gifford, are common in the biotechnology sector, reflecting investor confidence in companies with promising drug development pipelines. This filing indicates a substantial, established position rather than a new or rapidly changing stake.

Stakeholder Impact

• Shareholders: The substantial holding by a reputable investment firm like Baillie Gifford can be seen as a positive signal, potentially enhancing investor confidence.
• Management: The filing confirms that the shares are not held with the intent to influence or change control, providing a degree of stability from this large shareholder.
• Potential Investors: The presence of a significant institutional investor may attract further investment interest in Denali Therapeutics.

Next Steps

• Baillie Gifford & Co. will continue to hold and manage its investment in Denali Therapeutics Inc. on behalf of its clients.
• Further disclosures will be made if ownership levels change significantly, requiring amendments to this Schedule 13G.

Key Dates

Recommendation

This filing is a routine Schedule 13G disclosure indicating a significant, stable institutional holding. It does not provide new operational or financial data that would warrant a change in investment strategy. The 7.5% stake held by Baillie Gifford suggests a long-term perspective, but without further performance indicators, a 'hold' recommendation is appropriate for existing investors.

Keywords

Denali Therapeutics, Baillie Gifford, Schedule 13G, Institutional Investor, Beneficial Ownership, Common Stock, Investment Adviser